Loading
A phase 2 trial of Relmacabtagene autoleucel, Fludarabine, Cyclophosphamide in follicular lymphoma, run by Shanghai Ming Ju Biotechnology Co., Ltd., active and no longer recruiting.
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL is a phase 2 interventional study registered as NCT06093841 by Shanghai Ming Ju Biotechnology Co., Ltd., with 46 participants planned, started 2023-11-03 and due to reach its primary completion in 2024-01-21. Interventions recorded: Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide. Conditions listed: Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Relmacabtagene autoleucel, JW Therapeutics, CAR-T cell therapy.
Shares Fludarabine, Follicular lymphoma, Cyclophosphamide, CAR-T cell therapy.
Shares Relmacabtagene autoleucel, JW Therapeutics, CAR-T cell therapy.
Shares Fludarabine, Follicular lymphoma, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide, CAR-T cell therapy.
Shares Fludarabine, Cyclophosphamide, CAR-T cell therapy.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/